Company intelligence / Profile preview

Biomed Pharmaceuticals

San Jose, California, USAbiomedind.com ↗

Ownership: Private
Development stage: Other

Overview

Biomed Pharmaceuticals has developed a family of patented drugs targeting interconnected neurodegenerative and metabolic diseases. Lead assets are in Phase IIb/III trials for Alzheimer’s disease, ALS, major depressive disorder, diabetes/obesity-related conditions; an infusion system is FDA approved. The company leverages its Unified Acceleration Platform to address systemic drivers of chronic diseases rather than isolated symptoms. No pivotal trial readouts published yet; several programs are late-stage clinical candidates with broad potential applications.

Therapeutic areas: PsychiatryNeurologyMetabolic Disorders
Modalities: Small moleculePeptidesRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Biomed Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomed Pharmaceuticals.

Explore the full profile